Medivir Interim Report 1, 2003
INTERIM REPORT, 1 January - 31 March 2003 · MIV-210 producing positive results in ongoing phase I trial. · More opportunities for Cathepsin S inhibitor. · Successes in the explorative activities in the preclinical discovery have given a several new projects. · Lars Adlersson took up position as Medivir's CEO and President on 1 March. · Profit after financial items: SEK -38.6 (2.8) m. Net sales amounted to SEK 43.4 (86.6) m. · CCS' net sales increased to SEK 42.1 (35.0) m. Profit after financial items was SEK 8.8 (3.1) m. FOR MORE INFORMATION, PLEASE CONTACT: Rein Piir, CFO and VP IR, tel: +46 (0)70 853 7292 FORTHCOMING FINANCIAL INFORMATION The Annual General Meeting will be on 29 April 2003 The Second-quarter Interim Report 2003 will be published on 9 July 2003. The Third-quarter Interim Report 2003 will be published on 23 October 2003. Medivir's financial reports are available at its Website, www.medivir.se as of these dates, under the 'Financial Information' heading. The Medivir Group Medivir is an innovative, specialist research corporation that produces and develops pharmaceuticals. The company is located in Huddinge, Sweden and Cambridge, UK. Medivir's research is focused on developing new drug compounds based on proteases and polymerases as target enzymes. The group comprises Medivir AB, the subsidiaries Medivir UK Ltd. and CCS AB, plus second-tier subsidiaries CCS (UK) Ltd. and Nordic Care Sweden AB. CCS develops, manufactures and markets skin-care products and pharmaceuticals. Medivir has been quoted on the Stockholm Stock Exchange since 1996. Medivir's research portfolio includes projects against HIV, jaundice, shingles, cold sores, osteoporosis, RA (rheumatoid arthritis), asthma and MS (multiple sclerosis). Medivir has four projects in clinical development phases, two of which are entering phase III after completing phase II. One project is in phase I and one is in phase II. In the first stage, Medivir has some ten activities in explorative activities; the second, lead identification, encompasses three projects. The third stage, optimization, has one project, and two projects entering this phase. One project-MV026048-is in preclinical development, the stage closest to clinical development. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/04/29/20030429BIT01210/wkr0001.doc The full report http://www.waymaker.net/bitonline/2003/04/29/20030429BIT01210/wkr0002.pdf The full report